The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis

doi:10.5246/jcps.2019.07.048

Abstract

Abstract:

Inhaled drugs, including long-acting muscarinic antagonists (LAMAs), long-acting β₂-agonists (LABAs) and inhaled corticosteroids (ICSs), are the main therapeutic options for patients with chronic obstructive pulmonary disease (COPD). We conducted a systematic review and meta-analysis to compare the efficacy and safety of LAMA+LABA+ICS, LAMA+LABA and LABA+ICS therapies. The Pubmed, Embase and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing the efficacy (moderate-to-severe exacerbations, lung function and quality of life) and safety (adverse events (AEs), severe adverse events (SAEs), withdrawals due to AEs, deaths and pneumonia) of LAMA+LABA+ICS, LAMA+LABA and LABA+ICS in COPD patients. Two investigators independently searched eligible studies and extracted relevant information. The data were analyzed using the Review Manager software, and the quality of included studies was assessed using the Cochrane risk of bias tool. A total of 27 studies were included, and majority of the studies showed low risk of bias. Moderatetosevere exacerbations were lower after LAMA+LABA+ICS therapy compared with the LABA+ICS (RR = 0.66; 95% CI: 0.59–0.74) and LAMA+LABA therapies (RR = 0.88; 95% CI: 0.82–0.94). Lung function was significantly improved after LAMA+LABA+ICS compared with LAMA+ICS treatment. FEV1, peak FEV1 and trough FEV1 were significantly increased by 100 mL, 150 mL and 120 mL, respectively, in LAMA+LABA+ICS therapy compared with LAMA+ICS. In addition, LAMA+LABA therapy resulted in increased FEV1, peak FEV1 and trough FEV1 by 80 mL, 90 mL and 70 mL, respectively, compared with LAMA+ICS. SGRQ-total score was used to assess quality of life of COPD patients, which indicated that LAMA+LABA+ICS therapy was associated with slightly greater decrease compared with LABA+ICS (MD = –1.33; 95% CI: –2.35 to –0.30). No significant differences were found across all three treatment combinations in term of AEs, SAEs, withdrawals due to AEs and deaths. However, the risk of pneumonia was higher in the triple therapy group than that in the LABA+ICS (RR = 1.16; 95% CI: 1.01–1.33) or LAMA+LABA (RR = 1.31; 95% CI: 1.06–1.62) groups, and significantly lower in the LAMA+LABA group compared with LABA+ICS (RR = 0.64; 95% CI: 0.54–0.76). LAMA+LABA+ICS therapy offered greater efficacy and comparable safety compared with the LAMA+LABAor LABA+ICS therapies. However, triple therapy could increase the risk of pneumonia compared with LAMA+LABA or LABA+ICS therapies. People who have higher risk of pneumonia should carefully consider the use of triple therapy. LAMA+LABA therapy offered greater efficacy and lower risk of pneumonia to LABA+ICS therapy. Collectively, LAMA+LABA therapy might be a better choice than LABA+ICS.

Key words: COPD, LAMA+LABA+ICS, LAMA+LABA, LABA+ICS, Meta-analysis

CLC Number:

Supporting:

FEV1

Appendix figure 1 Forest plot demonstrating FEV1.

Peak FEV1

Appendix figure 2 Forest plot demonstrating peak FEV1.

SGRQ-total score

Appendix figure 3 Forest plot demonstrating SGRQ-total score.

Adverse events (AEs)

Appendix figure 4 Forest plot demonstrating AEs.

Severe adverse events (SAEs)

Appendix figure 5 Forest plot demonstrating SAEs.

Withdrawals due to AEs

Appendix figure 6 Forest plot demonstrating withdrawals due to AEs.

Deaths

Appendix figure 7 Forest plot demonstrating death.

Ruirui Zhou, Liqun Wang, Tong Sun, Ziyang Wu, Xiaohui Xie. The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 502-518.

References

[1] GOLD. Global Initiative for Chronic Obstructive Lung Disease (2018 REPORT). 2018. This article can be found online at https://goldcopd.org/wp-content/uploads/ 2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf

[2] Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Barker-Collo, S.; Bartels, D.H.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Bin Abdulhak, A.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.L.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380, 2095-2128.

[3] Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442.

[4] Cazzola, M.; Molimard, M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010, 23, 257-267.

[5] Martinez, F.J.; Fabbri, L.M.; Ferguson, G.T.; Orevillo, C.; Darken, P.; Martin, U.J.; Reisner, C. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017, 152, 1169-1178.

[6] Mahler, D.A.; Kerwin, E.; Ayers, T.; FowlerTaylor, A.; Maitra, S.; Thach, C.; Lloyd, M.; Patalano, F.; Banerji, D. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015, 192, 1068-1079.

[7] Wedzicha, J.A.; Decramer, M.; Ficker, J.H.; Niewoehner, D.E.; Sandström, T.; Taylor, A.F.; D'Andrea, P.; Arrasate, C.; Chen, H.; Banerji, D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013, 1, 199-209.

[8] Suissa, S.; Barnes, P.J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009, 34, 13-16.

[9] Nannini, L.J.; Lasserson, T.J.; Poole, P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012, CD006829.

[10] Nannini, L.J.; Poole, P.; Milan, S.J.; Kesterton, A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013, CD006826.

[11] Vogelmeier, C.F.; Criner, G.J.; Martinez, F.J.; Anzueto, A.; Barnes, P.J.; Bourbeau, J.; Celli, B.R.; Chen, R.C.; Decramer, M.; Fabbri, L.M.; Frith, P.; Halpin, D.M.; López Varela, M.V.; Nishimura, M.; Roche, N.; Rodriguez-Roisin, R.; Sin, D.D.; Singh, D.; Stockley, R.; Vestbo, J.; Wedzicha, J.A.; Agustí, A. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am. J. Respir. Crit. Care Med. 2017, 195, 557-582.

[12] Frith, P.A.; Thompson, P.J.; Ratnavadivel, R.; Chang, C.L.; Bremner, P.; Day, P.; Frenzel, C.; Kurstjens, N.; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015, 70, 519-527.

[13] Siler, T.M.; Kerwin, E.; Singletary, K.; Brooks, J.; Church, A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD. 2016, 13, 1-10.

[14] Ernst, P.; Suissa, S. Systemic effects of inhaled corticosteroids. Curr. Opin. Pulm. Med. 2012, 18, 85-89.

[15] Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0. This article can be found online at http://www.cochrane-handbook.org.

[16] Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ. 2003, 327, 557-560.

[17] Aaron, S.D.; Vandemheen, K.L.; Fergusson, D.; Maltais, F.; Bourbeau, J.; Goldstein, R.; Balter, M.; O’Donnell, D.; McIvor, A.; Sharma, S.; Bishop, G.; Anthony, J.; Cowie, R.; Field, S.; Hirsch, A.; Hernandez, P.; Rivington, R.; Road, J.; Hoffstein, V.; Hodder, R.; Marciniuk, D.; McCormack, D.; Fox, G.; Cox, G.; Prins, H.B.; Ford, G.; Bleskie, D.; Doucette, S.; Mayers, I.; Chapman, K.; Zamel, N.; FitzGerald, M.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007, 146, 545-555.

[18] Rabe, K.F.; Timmer, W.; Sagkriotis, A.; Viel, K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008, 134, 255-262.

[19] Singh, D.; Papi, A.; Corradi, M.; Pavlišová, I.; Montagna, I.; Francisco, C.; Cohuet, G.; Vezzoli, S.; Scuri, M.; Vestbo, J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016, 388, 963-973.

[20] Singh, D.; Worsley, S.; Zhu, C.Q.; Hardaker, L.; Church, A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm. Med. 2015, 15, 91.

[21] Sousa, A.R.; Riley, J.H.; Church, A.; Zhu, C.Q.; Punekar, Y.S.; Fahy, W.A. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim. Care Respir. Med. 2016, 26, 16031.

[22] Vogelmeier, C.F.; Bateman, E.D.; Pallante, J.; Alagappan, V.K.; D’Andrea, P.; Chen, H.; Banerji, D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013, 1, 51-60.

[23] Vogelmeier, C.F.; Gaga, M.; Aalamian-Mattheis, M.; Greulich, T.; Marin, J.M.; Castellani, W.; Ninane, V.; Lane, S.; Nunez, X.; Patalano, F.; Clemens, A.; Kostikas, K.; CRYSTAL study investigators. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir. Res. 2017, 18, 140.

[24] Zhong, N.S.; Wang. C.Z.; Zhou, X.D.; Zhang, N.F.; Humphries, M.; Wang, L.D.; Thach, C.; Patalano, F.; Banerji, D.; Sannigrahi, S. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Chronic Obstr. Pulm. Dis. 2015, 10, 1015-1026.

[25] Beeh, K.M.; Derom, E.; Echave-Sustaeta, J.; Grönke, L.; Hamilton, A.; Zhai, D.M.; Bjermer, L. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int. J. Chronic Obstr. Pulm. Dis. 2016, 11, 193-205.

[26] Lipson, D.A.; Barnhart, F.; Brealey, N.; Brooks, J.; Criner, G.J.; Day, N.C.; Dransfield, M.T.; Halpin, D.M.G.; Han, M.K.; Jones, C.E.; Kilbride, S.; Lange, P.; Lomas, D.A.; Martinez, F.J.; Singh, D.; Tabberer, M.; Wise, R.A.; Pascoe, S.J.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018, 378, 1671-1680.

[27] Lipson, D.A.; Barnacle, H.; Birk, R.; Brealey, N.; Locantore, N.; Lomas, D.A.; Ludwig-Sengpiel, A.; Mohindra, R.; Tabberer, M.; Zhu, C.Q.; Pascoe, S.J. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017, 196, 438-446.

[28] Papi, A.; Vestbo, J.; Fabbri, L.; Corradi, M.; Prunier, H.; Cohuet, G.; Guasconi, A.; Montagna, I.; Vezzoli, S.; Petruzzelli, S.; Scuri, M.; Roche, N.; Singh, D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018, 391, 1076-1084.

[29] Tabberer, M.; Lomas, D.A.; Birk, R.; Brealey, N.; Zhu, C.Q.; Pascoe, S.; Locantore, N.; Lipson, D.A. Once-daily triple therapy in patients with COPD: patient-reported symptoms and quality of life. Adv. Ther. 2018, 35, 56-71.

[30] Chapman, K.R.; Hurst, J.R.; Frent, S.M.; Larbig, M.; Fogel, R.; Guerin, T.; Banerji, D.; Patalano, F.; Goyal, P.; Pfister, P.; Kostikas, K.; Wedzicha, J.A. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 2018, 198, 329-339.

[31] Cazzola, M.; Andò, F.; Santus, P.; Ruggeri, P.; Di Marco, F.; Sanduzzi, A.; D’Amato, M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 2007, 20, 556-561.

[32] Frith, P.A.; Thompson, P.J.; Ratnavadivel, R.; Chang, C.L.; Bremner, P.; Day, P.; Frenzel, C.; Kurstjens, N.; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015, 70, 519-527.

[33] Hoshino, M.; Ohtawa, J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration. 2013, 86, 280-287.

[34] Siler, T.M.; Kerwin, E.; Singletary, K.; Brooks, J.; Church, A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD. 2016, 13, 1-10.

[35] Siler, T.M.; Kerwin, E.; Sousa, A.R.; Donald, A.; Ali, R.H.; Church, A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir. Med. 2015, 109, 1155-1163.

[36] Magnussen, H.; Disse, B.; Rodriguez-Roisin, R.; Kirsten, A.; Watz, H.; Tetzlaff, K.; Towse, L.; Finnigan, H.; Dahl, R.; Decramer, M.; Chanez, P.; Wouters, E.F.; Calverley, P.M.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014, 371, 1285-1294.

[37] Donohue, J.F.; Worsley, S.; Zhu, C.Q.; Hardaker, L.; Church, A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir. Med. 2015, 109, 870-881.

[38] Wedzicha, J.A.; Banerji, D.; Chapman, K.R.; Vestbo, J.; Roche, N.; Ayers, R.T.; Thach, C.; Fogel, R.; Patalano, F.; Vogelmeier, C.F.; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016, 374, 2222-2234.

[39] Vogelmeier, C.; Paggiaro, P.L.; Dorca, J.; Sliwinski, P.; Mallet, M.; Kirsten, A.M.; Beier, J.; Seoane, B.; Segarra, R.M.; Leselbaum, A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur. Respir. J. 2016, 48, 1030-1039.

[40] Ferguson, G.T.; Rabe, K.F.; Martinez, F.J.; Fabbri, L.M.; Wang, C.; Ichinose, M.; Bourne, E.; Ballal, S.; Darken, P.; DeAngelis, K.; Aurivillius, M.; Dorinsky, P.; Reisner, C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 2018, 6, 747-758.

[41] Frith, P.A.; Ashmawi, S.; Krishnamurthy, S.; Gurgun, A.; Hristoskova, S.; Pilipovic, V.; Hamann, A.M.; Backer, A.; Olsson, P.; Kostikas, K.; Diaz, D.V.; FLASH Investigators. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology. 2018, 23, 1152-1159.

[42] Zheng, J.P.; Zhong, N.S.; Wang, C.Z.; Huang, Y.J.; Chen, P.; Wang, L.M.; Hui, F.X.; Zhao, L.; Wang, H.Y.; Luo, L.D.; Du, X.; Han Goh, A.; Lipson, D.A. The efficacy and safety of once-daily fluticasone furoate/umeclidinium/vilanterol versus twice-daily budesonide/formoterol in a subgroup of patients from China with symptomatic COPD at risk of exacerbations (FULFIL trial). COPD. 2018, 15, 334-340.

[43] Zhao, D.G.; Ling, C.H.; Guo, Q.; Jin, J.; Xu, H. Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease. Exp. Ther. Med. 2018, 16, 4578-4584.

[44] Melani, A.S. Long-acting muscarinic antagonists. Expert Rev. Clin. Pharmacol. 2015, 8, 479-501.

[45] Karner, C.; Chong, J.; Poole, P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014, CD009285.

[46] Kesten, S.; Casaburi, R.; Kukafka, D.; Cooper, C.B. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3, 127-136.

[47] Casaburi, R.; Kukafka, D.; Cooper, C.B.; Witek, T.J. Jr, Kesten, S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005, 127, 809-817.

[48] Yang, I.A.; Clarke, M.S.; Sim, E.H.; Fong, K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012, CD002991.

[49] Vestbo, J.; Leather, D.; Diar Bakerly, N.; New, J.; Gibson, J.M.; McCorkindale, S.; Collier, S.; Crawford, J.; Frith, L.; Harvey, C.; Svedsater, H.; Woodcock, A.; Salford Lung Study Investigators. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N. Engl. J. Med. 2016, 375, 1253-1260.

[50] Vestbo, J.; Anderson, J.A.; Brook, R.D.; Calverley, P.M.; Celli, B.R.; Crim, C.; Martinez, F.; Yates, J.; Newby, D.E.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016, 387, 1817-1826.

[51] Mario, C.; Paola, R.; Luigino, C. Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur. Respir. J. 2018, doi: 10.1183/ 13993003. 01586-2018.

[52] Crim, C.; Dransfield, M.T.; Bourbeau, J.; Jones, P.W.; Hanania, N.A.; Mahler, D.A.; Vestbo, J.; Wachtel, A.; Martinez, F.J.; Barnhart, F.; Lettis, S.; Calverley, P.M. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann. Am. Thorac. Soc. 2015, 12, 27-34.

[53] Crim, C.; Calverley, P.M.A.; Anderson, J.A.; Holmes, A.P.; Kilbride, S.; Martinez, F.J.; Brook, R.D.; Newby, D.E.; Yates, J.C.; Celli, B.R.; Vestbo, J.; SUMMIT investigators. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respir. Med. 2017, 131, 27-34.

[54] Zheng, Y.Y.; Zhu, J.H.; Liu, Y.Y.; Lai, W.G.; Lin, C.Y.; Qiu, K.F.; Wu, J.Y.; Yao, W.M. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018, 363, k4388.